Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVL combination therapy in newly diagnosed elderly AML/MDS
ChiCTR2500103716Phase 2Not yet recruiting
- Sponsor
- Army Medical Center of PLA
- Start
- Jun 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine, venetoclax and lenalidomide in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Army Medical Center of PLA. Primary endpoint: Objective response rate. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
azacitidinevenetoclaxlenalidomide
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR2500103716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103716.